Car Nk
anti-CD19 CAR-NK
anti-CD19 CAR-NK is flagged as a platform signal because it has an active early-phase oncology cell-therapy trial at Second Affiliated Hospital, School of Medicine, Zhejiang University, with a possible patent signal linked through modality_match. Manual review is still required.
Phase1 · Unknown
View asset